Dotinurad, a URAT1 selective inhibitor, has been shown to ameliorate insulin resistance by attenuating hepatic steatosis and promoting brown adipose tissue re-browning in mice [85]. This evidence concerns the gene SLC22A12 and Insulin resistance.